TY - JOUR
T1 - Informal caregiving burden in advanced non-small cell lung cancer
T2 - The HABIT study
AU - Gridelli, Cesare
AU - Ferrara, Carmine
AU - Guerriero, Ciro
AU - Palazzo, Salvatore
AU - Grasso, Giuseppe
AU - Pavese, Ida
AU - Satta, Francesco
AU - Bajetta, Emilio
AU - Cortinovis, Diego
AU - Barbieri, Fausto
AU - Gebbia, Vittorio
AU - Grossi, Francesco
AU - Novello, Silvia
AU - Baldini, Editta
AU - Gasparini, Giampietro
AU - Latino, Walter
AU - Durante, Emilia
AU - Giustini, Lucio
AU - Negrini, Cristina
PY - 2007/6
Y1 - 2007/6
N2 - INTRODUCTION: This study's aim was to assess economic data regarding the home assistance burden for advanced non-small cell lung cancer (NSCLC) patients in Italy. PATIENTS AND METHODS: One hundred four NSCLC patients in second-line chemotherapy (2LC) or in supportive therapy (ST) were enrolled in 18 Italian oncology departments and were observed for 3 months. The main caregiver's workload was assessed monthly by a task scale; other caregivers' activities were also registered. Eastern Cooperative Oncology Group performance status was assessed by physicians, and patients completed the Lung Cancer Symptoms (LCS) subscale. Formal caregiving time was valued according to market prices; informal caregiving hours were valued using the wage rate for an equivalent service. Covariance analysis was performed to check for influential factors in assistance costs. RESULTS: The mean age of the total sample was 65.5 years, and prevalence of males was over 80%. In over 70% of cases, the principal caregiver was patient's spouse, living with the patient and not working. Principal caregiver support was the main cost item: &OV0556;2.368 in 2LC and &OV0556;2.805 in ST, representing 74% of total trimonthly assistance costs. Regression analysis showed a positive correlation between the severity of symptoms and the costs of assistance.The caregiving burden was higher in patients with bone and/or cerebral metastases; other metastasis sites seemed to have no impact on assistance costs. CONCLUSION: Considering quality of life as the ultimate health outcome, clinicians are challenged to contribute to a research and policy agenda that holds burden of care in due consideration.
AB - INTRODUCTION: This study's aim was to assess economic data regarding the home assistance burden for advanced non-small cell lung cancer (NSCLC) patients in Italy. PATIENTS AND METHODS: One hundred four NSCLC patients in second-line chemotherapy (2LC) or in supportive therapy (ST) were enrolled in 18 Italian oncology departments and were observed for 3 months. The main caregiver's workload was assessed monthly by a task scale; other caregivers' activities were also registered. Eastern Cooperative Oncology Group performance status was assessed by physicians, and patients completed the Lung Cancer Symptoms (LCS) subscale. Formal caregiving time was valued according to market prices; informal caregiving hours were valued using the wage rate for an equivalent service. Covariance analysis was performed to check for influential factors in assistance costs. RESULTS: The mean age of the total sample was 65.5 years, and prevalence of males was over 80%. In over 70% of cases, the principal caregiver was patient's spouse, living with the patient and not working. Principal caregiver support was the main cost item: &OV0556;2.368 in 2LC and &OV0556;2.805 in ST, representing 74% of total trimonthly assistance costs. Regression analysis showed a positive correlation between the severity of symptoms and the costs of assistance.The caregiving burden was higher in patients with bone and/or cerebral metastases; other metastasis sites seemed to have no impact on assistance costs. CONCLUSION: Considering quality of life as the ultimate health outcome, clinicians are challenged to contribute to a research and policy agenda that holds burden of care in due consideration.
KW - Assistance burden
KW - Informal caregiving
KW - NSCLC
UR - http://www.scopus.com/inward/record.url?scp=34447133500&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34447133500&partnerID=8YFLogxK
U2 - 10.1097/01.JTO.0000275342.47584.f3
DO - 10.1097/01.JTO.0000275342.47584.f3
M3 - Article
C2 - 17545841
AN - SCOPUS:34447133500
SN - 1556-0864
VL - 2
SP - 475
EP - 480
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 6
ER -